pc - give us a hint, page-3

Most shareholders believe Biota has the products to be a blue ship company. There is Relenza, LANI/Inavir and HRV. Yet the sp is languishing at a dollar. Why?

Why is Relenza sales such a poor performer compare to Tamiflu?
Is the current management responsible for GSK poor performance?
GSK offered to settle the law suit for $130m and return Relenza to Biota. Management turned down that offer, spend $30m in legal costs and then settled for $20m and most importantly allowed GSK to use Relenza to sell GSK vaccines and with no serious effort to market Relenza.
Why should the current management not accountable?

LANI/Inavir - Biota has not score any significant funding under PC and the current management while other companies with lesser products are showered with fundings. Why? What has the current management done other than to imply ROW is dependant on getting funding. The management had postponed their own target for ROW licensing a few times. For such a promising drug, can Bozo the clown do better?

Is management responsible for talking down the share price? Why is it that each time PC make an announcement the share price get hammered? The recent announcement is a classic - there was nothing new in the announcement as the data were already known facts, yet the price plummeted. Why is the CEO not accountable for talking down the share price?